Aurinia Pharmaceuticals Inc. AUPH
Institutional shares held
65.2 Million
1.1M
calls
772K
puts
Total value of holdings
$579M
$9.77M
calls
$6.86M
puts
Market Cap
$1.26B
141,892,000
Shares Out.
Institutional ownership
45.93%
# of Institutions
240
We take great care to ensure that the data presented and summarized in this overview for Aurinia Pharmaceuticals Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AUPH
View all-
Tang Capital Management LLC San Diego, CA10MShares$89.1 Million5.24% of portfolio
-
Black Rock Inc. New York, NY9.27MShares$82.3 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5MShares$44.4 Million0.61% of portfolio
-
Nea Management Company, LLC Timonium, MD3.97MShares$35.3 Million3.03% of portfolio
-
State Street Corp Boston, MA2.85MShares$25.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.37MShares$21 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.97MShares$17.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.73MShares$15.4 Million0.0% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA1.64MShares$14.6 Million0.01% of portfolio
-
Goldman Sachs Group Inc New York, NY1.63MShares$14.5 Million0.0% of portfolio
Latest Institutional Activity in AUPH
Top Purchases
Top Sells
About AUPH
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Insider Transactions at AUPH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 07
2025
|
Greg Keenan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,305
-5.13%
|
$66,440
$8.23 P/Share
|
|
Mar 04
2025
|
Peter Greenleaf Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
164,947
-8.44%
|
$1,154,629
$7.92 P/Share
|
|
Mar 04
2025
|
Matthew Maxwell Donley Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
58,991
-7.98%
|
$412,937
$7.92 P/Share
|
|
Mar 04
2025
|
Stephen P. Robertson EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
57,607
-10.16%
|
$403,249
$7.92 P/Share
|
|
Mar 04
2025
|
Joseph M Miller Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
56,154
-8.86%
|
$393,078
$7.92 P/Share
|
|
Mar 04
2025
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
748,038
+2.44%
|
$5,984,304
$8.0 P/Share
|
|
Mar 03
2025
|
Greg Keenan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,239
-7.03%
|
$97,912
$8.0 P/Share
|
|
Mar 03
2025
|
Peter Greenleaf Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
195,593
-9.1%
|
$1,564,744
$8.0 P/Share
|
|
Mar 03
2025
|
Peter Greenleaf Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
333,705
+13.44%
|
-
|
|
Mar 03
2025
|
Matthew Maxwell Donley Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
65,902
-8.18%
|
$527,216
$8.0 P/Share
|
|
Mar 03
2025
|
Matthew Maxwell Donley Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
135,567
+14.41%
|
-
|
|
Mar 03
2025
|
Stephen P. Robertson EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
64,872
-10.27%
|
$518,976
$8.0 P/Share
|
|
Mar 03
2025
|
Stephen P. Robertson EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
102,406
+13.95%
|
-
|
|
Mar 03
2025
|
Joseph M Miller Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
61,859
-8.9%
|
$494,872
$8.0 P/Share
|
|
Mar 03
2025
|
Joseph M Miller Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
114,711
+14.16%
|
-
|
|
Mar 03
2025
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
452,682
+2.38%
|
$3,168,774
$8.0 P/Share
|
|
Feb 28
2025
|
Greg Keenan Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
62,583
+26.45%
|
-
|
|
Feb 28
2025
|
Peter Greenleaf Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
290,728
+13.8%
|
-
|
|
Feb 28
2025
|
Matthew Maxwell Donley Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
82,781
+11.0%
|
-
|
|
Feb 28
2025
|
Stephen P. Robertson EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
84,106
+13.71%
|
-
|
Last 12 Months Summary
Buy / Acquisition
4.19M
Shares
From
13
Insiders
| Grant, award, or other acquisition | 1.36M shares |
|---|---|
| Open market or private purchase | 2.8M shares |
| Exercise of conversion of derivative security | 35.8K shares |
Sell / Disposition
775K
Shares
From
8
Insiders
| Open market or private sale | 775K shares |
|---|